Kezdőlap・Részvénylista・Allogene Therapeutics Inc

Allogene Therapeutics Inc

Lezárt

SzektorEgészségügy

2 2.04

Vétel Eladás

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

1.95

Maximum

2.02

Fő mutatók
By Trading Economics
Bevétel	-3.8M -43M
Egy részvényre jutó nyereség	-0.18
Munkavállalók	150
EBITDA	-91K -39M

Ajánlások
By TipRanks
Ajánlások	Erős vétel
12 hónapos előrejelzés	+407.61% upside

Osztalékok
By Acuity
Következő eredményjelentés	2026. aug. 12.

Piaci statisztika
By TradingEconomics
Piaci kapitalizáció	-152M 635M
Előző nyitás	-0.04
Előző zárás	2

Allogene Therapeutics Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 7. 19:16 UTC

Correlated Moves

Biotechnology stocks are rising, boosting Allogene Therapeutics shares. The ARK Genomic Revolution ETF has also increased, reflecting positive sector momentum.

2026. aug. 6. 19:46 UTC

Correlated Moves

Allogene Therapeutics shares are lower, reflecting broader market trends, as the Russell 2000 Index also declined during Thursday's session.

2026. aug. 5. 22:01 UTC

Allogene Therapeutics Inc shares are lower in after-market trading, reflecting a pullback from earlier gains amid broader market volatility following weaker U.S. job growth data.

2026. aug. 3. 20:06 UTC

Allogene Therapeutics Inc. shares are trading lower, continuing a decline since Friday's close, despite broader market gains in the S&P 500 and Nasdaq 100.

2026. júl. 30. 20:04 UTC

Correlated Moves

Event

Allogene Therapeutics receives RMAT and Fast Track designations from the FDA for cema-cel, contributing to gains in shares today.

2026. júl. 29. 23:51 UTC

Event

Correlated Moves

Allogene Therapeutics receives FDA RMAT and Fast Track designations for cema-cel, boosting shares higher in after-market hours. The Russell 2000 Index's rise may also contribute.

2026. júl. 28. 20:02 UTC

Allogene Therapeutics Inc shares are lower amid negative market sentiment following a significant sell-off in technology stocks across Asian markets.

2026. júl. 27. 18:07 UTC

Allogene Therapeutics Inc shares are higher today, despite earlier fluctuations. The market backdrop features a decline in oil prices, easing inflation concerns.

2026. júl. 24. 19:46 UTC

Correlated Moves

Allogene Therapeutics Inc is lower today amid broader market declines, with the Russell 2000 Index down and oil price volatility impacting the biotechnology sector.

2026. júl. 23. 22:56 UTC

Allogene Therapeutics Inc. shares are roughly flat in after-market trading, remaining below their 20-day moving average and near the lower end of their one-month range.

2026. júl. 22. 20:13 UTC

Correlated Moves

Allogene Therapeutics Inc shares are lower in after-market trading, reflecting broader market declines amid rising crude oil prices and geopolitical tensions.

2026. júl. 21. 18:46 UTC

Correlated Moves

Social Media

Allogene Therapeutics shares are higher following positive TRAVERSE trial results for ALLO-316, which showed a 25% overall response rate in patients.

2026. júl. 20. 23:26 UTC

Allogene Therapeutics Inc. shares are higher in after-market trading, with no specific news identified. Broader market volatility continues to influence investor sentiment.

Társak összehasonlítása

Árváltozás

Allogene Therapeutics Inc Előrejelzés

Célár

By TipRanks

407.61% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 10 USD 407.61%

Magas 14 USD

Alacsony 7 USD

6 Wall Street elemző 12 hónapos célárain alapulva a(z)Allogene Therapeutics Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

6 ratings

Vétel

Tartás

Eladás

6 Wall Street elemző célárain alapulva a(z)Allogene Therapeutics Inc termékhez az elmúlt 3 hónapban.

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

Rólunk Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.